Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of carnosic acid in preparation of drugs for treating rheumatoid arthritis

A technology of carnosic acid and rheumatoid, which is applied in the application field of carnosic acid in the treatment of rheumatoid arthritis drugs, and can solve problems such as infection, seriousness, and malignant tumors

Inactive Publication Date: 2018-03-23
GUANGXI MEDICAL UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term intake of these drugs can cause serious infections and even malignant tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carnosic acid in preparation of drugs for treating rheumatoid arthritis
  • Application of carnosic acid in preparation of drugs for treating rheumatoid arthritis
  • Application of carnosic acid in preparation of drugs for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0049] Carnosic acid inhibits inflammatory responses and joint destruction in osteoclasts and fibroblast-like synoviocytes in vivo and collagen-induced arthritis in rats in vitro

[0050] 1. Materials and methods

[0051] 1. Materials and their sources

[0052] Carnosic acid (purity ≥98%) was purchased from Master Biotechnology Co., Ltd. (Chengdu, Sichuan, China) and dissolved in dimethyl sulfoxide. α-minimal essential medium and fetal calf serum were purchased from TRACE (Sydney, Australia). Recombinant macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) were purchased from Andy Biotechnology Co., Ltd. (Minneapolis, USA). MTS reagent and luciferase assay reagent were obtained from Promega (Sydney, Australia). Antibodies IκBα, ERK, JNK, p38, phosphorylated (p)ERK, p-p38, p-JNK, and β-actin were purchased from Santa Cruz Biotechnology (Dallas, CA, USA). Anti-NFATc1 and anti-c-fos antibodies were purchased from BD Bioscienc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of carnosic acid in preparation of drugs for treating rheumatoid arthritis. The in-vitro experiment and in-vivo experiment show that the carnosic acid is capable ofinhibiting the expression of proinflammatory factors as well as inhibiting the production of nuclear factor NF-kappa-B receptor activator of nuclear factor kappa-B ligand (RANKL); more importantly, the research shows that the carnosic acid is capable of inhibiting osteoclast production and bone resorption in vitro, can perform treatment protection on joint injury in vivo, and has the effect of resisting bone injury during the development of rheumatoid arthriti; the further biochemical analysis shows that the carnosic acid is able to inhibit the activation effects of RANKL induced nuclear factor -kappa-B and mitogen activated protein kinase (p38 and JNK) and enables decrease of NFATc1. The abovementioned results show that the carnosic acid can be developed to prepare the drugs for treatingpatients with rheumatoid arthritis, in order to prevent inflammation and joint injury.

Description

technical field [0001] The invention belongs to the technical field of treating rheumatoid arthritis, and in particular relates to the application of carnosic acid in medicine for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a chronic autoimmune disease characterized by progressive synovial inflammation and joint damage. Due to the complexity of the treatment response of patients with rheumatoid arthritis, how to treat it remains the biggest problem we face. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used clinically to reduce inflammation, but their efficacy in preventing bone damage in rheumatoid arthritis is weak. Although reliever antirheumatic drugs, including inhibitors of alpha-tumor necrosis factor (TNFα) and interleukin-1β (IL-1β), have been shown to be an effective and promising treatment for patients with rheumatoid arthritis method. However, long-term intake of these drugs can cause serious infections and even mali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61P19/02A61P29/00
CPCA61K31/192
Inventor 徐家科刘梅程建文赵劲民
Owner GUANGXI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com